Gut microbiome therapies modestly lower blood sugar in type 2 diabetes

Type 2 diabetes is at heart a problem of blood sugar control, and the gut microbiome has emerged as a possible lever on it. Probiotics, prebiotics and other microbiome-targeted therapies are widely sold, but individual trials have been small and inconsistent. Whether reshaping gut bacteria genuinely improves glucose metabolism, or merely shifts a few laboratory markers, matters for the huge number of people managing the condition day to day. This review set out to pool everything the randomised evidence can currently say on the question.

Researchers searched four databases for randomised controlled trials of gut microbiome-targeted therapies in people with type 2 diabetes. They found 54 trials covering 60 intervention groups and 3390 participants in total. Outcomes included fasting glucose, glucose measured after a meal, fasting insulin, HbA1c and insulin resistance, alongside inflammatory markers and the make-up of the gut bacteria themselves. Subgroup analyses examined region, type of therapy, number of probiotic strains, dose, duration, average age and baseline body mass index.

Fasting glucose fell by an average of 7.97 mg/dL, and glucose measured two hours after a meal dropped by 43.30 mg/dL. HbA1c, the longer-run marker of blood sugar control, fell by 0.28%, and fasting insulin and insulin resistance scores also improved. Inflammatory markers moved in a favourable direction: high-sensitivity C-reactive protein, tumour necrosis factor alpha and lipopolysaccharides fell, while the anti-inflammatory interleukin-10 rose. Beneficial microbes, including Actinobacteria and Lactobacillus, became more abundant. The authors describe the overall improvements as modest.

This is one of the larger pooled analyses of microbiome-targeted therapies in type 2 diabetes, and it lands on a consistent if modest benefit across several glucose measures at once. It supports the broader idea that gut bacteria are an active player in metabolic health rather than bystanders. However, the included trials disagreed with each other, and long-term data are limited, so the durability of the effect is unknown. The authors explicitly call for large-scale trials before firmer conclusions are drawn.

For someone managing type 2 diabetes or watching their metabolic health, this is a reason to take the gut microbiome seriously as one influence on blood sugar, while remembering that the improvements were modest averages across many different products, strains and doses. The pooled result cannot tell you which specific therapy did the work. It also describes an add-on effect in trial conditions, not a replacement for established diabetes care, and how long the benefit lasts remains an open question.